NUT midline carcinoma (NMC) is a rare and aggressive squamous carcinoma subtype that is mainly driven by the BRD4-NUT fusion oncoprotein, and BET (bromodomain extra-terminal) inhibitors were found to have a high efficacy in treating NMC [209]. This evidence concerns the gene NUTM1 and nut midline carcinoma.